Anpath Group, Inc., a manufacturer and producer of eco-friendly cleaning and disinfecting products that help prevent the spread of infectious microorganisms, recently announced that the company has retained the investment banking firm Laidlaw & Company to provide investment banking and financial advisory services, as well as advice on strategic transactions, including possible technology licensing arrangements.

Anpath Group, Inc., through its wholly-owned subsidiary, EnviroSystems, Inc., specializes in safe infection prevention technologies designed to eradicate infectious microorganisms while offering a favorable safety and environmental profile. Laidlaw & Company personalized investment advice and skillful execution to private and public institutions, and has developed long-term relationships with many of the top portfolio managers with special attention to technology and biotechnology investors.

J. Lloyd Breedlove, president and chief executive officer of Anpath Group, Inc., stated, “We believe the market and the need for safe and environmentally responsible infection prevention is rapidly growing. With the assistance of

...

Sometime during the middle of the year, Genentech (DNA) shareholders are going to get $95 in cash for each share of Genentech stock they own. In total, nearly $47 billion in funds are expected to be returned to biotechnology investors.We've come up with an effective "basket approach" to re-deploy those funds back into the biotech sector -- in search of the next Genentech.Antisense Makes a Lot of SenseFor a little over $13, investors can pick up one share of Isis Pharmaceuticals (ISIS). Isis is the market leader in antisense technology.We've made it no secret in the past -- we are big fans of antisense. We view the drug discovery engine fueled by Isis' antisense technology very similar to the power of Genentech's recombinant DNA and monoclonal antibody technology breakthroughs of the 1980's. Antisense drugs are still in their infancy, ...